Geron Corp. (GERN) Stock Price Down 1.5%
Shares of Geron Corp. (NASDAQ:GERN) traded down 1.5% during mid-day trading on Monday . The company traded as low as $2.64 and last traded at $2.66, with a volume of 437,506 shares changing hands. The stock had previously closed at $2.70.
A number of analysts have issued reports on the company. FBR & Co reaffirmed a “buy” rating on shares of Geron Corp. in a report on Sunday, May 8th. Zacks Investment Research raised Geron Corp. from a “hold” rating to a “strong-buy” rating and set a $3.00 target price on the stock in a report on Friday, August 5th. Finally, BTIG Research assumed coverage on Geron Corp. in a report on Friday, August 19th. They issued a “neutral” rating on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Geron Corp. currently has a consensus rating of “Buy” and an average target price of $6.20.
The stock has a market cap of $423.31 million and a P/E ratio of 332.50. The firm has a 50 day moving average of $2.70 and a 200 day moving average of $2.81.
Geron Corp. (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. During the same period in the prior year, the company earned ($0.06) earnings per share. The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.38 million. The firm’s quarterly revenue was down 15.9% on a year-over-year basis. On average, equities research analysts expect that Geron Corp. will post ($0.23) earnings per share for the current fiscal year.
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.